Addex Therapeutics (ADXN) Competitors $8.27 +0.00 (+0.05%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADXN vs. KZR, CLNN, OKUR, RNTX, FGEN, BDRX, ESLA, MIRA, DYAI, and SCYXShould you be buying Addex Therapeutics stock or one of its competitors? The main competitors of Addex Therapeutics include Kezar Life Sciences (KZR), Clene (CLNN), OnKure Therapeutics (OKUR), Rein Therapeutics (RNTX), FibroGen (FGEN), Biodexa Pharmaceuticals (BDRX), Estrella Immunopharma (ESLA), MIRA Pharmaceuticals (MIRA), Dyadic International (DYAI), and SCYNEXIS (SCYX). These companies are all part of the "pharmaceutical products" industry. Addex Therapeutics vs. Its Competitors Kezar Life Sciences Clene OnKure Therapeutics Rein Therapeutics FibroGen Biodexa Pharmaceuticals Estrella Immunopharma MIRA Pharmaceuticals Dyadic International SCYNEXIS Kezar Life Sciences (NASDAQ:KZR) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings. Does the media prefer KZR or ADXN? In the previous week, Kezar Life Sciences had 1 more articles in the media than Addex Therapeutics. MarketBeat recorded 2 mentions for Kezar Life Sciences and 1 mentions for Addex Therapeutics. Kezar Life Sciences' average media sentiment score of 0.93 equaled Addex Therapeutics'average media sentiment score. Company Overall Sentiment Kezar Life Sciences Positive Addex Therapeutics Positive Do institutionals & insiders have more ownership in KZR or ADXN? 67.9% of Kezar Life Sciences shares are owned by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are owned by institutional investors. 10.4% of Kezar Life Sciences shares are owned by company insiders. Comparatively, 15.0% of Addex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts prefer KZR or ADXN? Kezar Life Sciences presently has a consensus target price of $39.50, suggesting a potential upside of 816.47%. Addex Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 263.37%. Given Kezar Life Sciences' higher possible upside, equities research analysts clearly believe Kezar Life Sciences is more favorable than Addex Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kezar Life Sciences 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Addex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is KZR or ADXN more profitable? Addex Therapeutics has a net margin of 3,584.49% compared to Kezar Life Sciences' net margin of 0.00%. Addex Therapeutics' return on equity of -54.27% beat Kezar Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Kezar Life SciencesN/A -61.15% -50.27% Addex Therapeutics 3,584.49%-54.27%-49.15% Which has more risk and volatility, KZR or ADXN? Kezar Life Sciences has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Addex Therapeutics has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500. Which has higher earnings & valuation, KZR or ADXN? Addex Therapeutics has lower revenue, but higher earnings than Kezar Life Sciences. Addex Therapeutics is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKezar Life Sciences$7M4.50-$83.74M-$10.82-0.40Addex Therapeutics$170.62K51.29$8.02M-$0.34-24.28 SummaryAddex Therapeutics beats Kezar Life Sciences on 9 of the 14 factors compared between the two stocks. Get Addex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXN vs. The Competition Export to ExcelMetricAddex TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.77M$2.50B$5.70B$9.51BDividend YieldN/A1.75%4.69%4.01%P/E Ratio-24.289.0528.0720.05Price / Sales51.29757.64448.5799.42Price / CashN/A165.2136.2258.56Price / Book0.805.168.665.87Net Income$8.02M$30.99M$3.25B$258.55M7 Day Performance9.50%7.74%4.20%2.23%1 Month Performance-5.27%16.18%10.82%12.76%1 Year Performance3.20%-1.03%34.70%19.36% Addex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXNAddex Therapeutics2.1843 of 5 stars$8.26-0.2%$30.00+263.4%+3.4%$8.77M$170.62K-24.2830Gap UpKZRKezar Life Sciences4.1969 of 5 stars$4.30-1.1%$39.50+818.6%-32.4%$31.78M$7M-0.4060CLNNClene3.4299 of 5 stars$3.87+1.3%$40.00+933.6%-19.2%$31.58M$340K-0.96100OKUROnKure Therapeutics3.4043 of 5 stars$2.32-0.4%$32.33+1,293.7%N/A$31.48MN/A-0.44N/APositive NewsRNTXRein TherapeuticsN/A$1.44+1.4%N/AN/A$31.46MN/A-0.509FGENFibroGen4.5894 of 5 stars$7.56-1.2%$250.00+3,206.9%-76.9%$30.92M$7.00M-3.02570Positive NewsBDRXBiodexa Pharmaceuticals0.2905 of 5 stars$0.85+0.7%N/AN/A$30.86M$470K0.0020Positive NewsESLAEstrella Immunopharma3.3035 of 5 stars$0.84-1.5%$16.00+1,804.8%-40.7%$30.86MN/A-3.23N/AGap DownMIRAMIRA Pharmaceuticals2.5791 of 5 stars$1.68-6.7%$14.00+733.3%-26.3%$30.45MN/A-3.292DYAIDyadic International3.304 of 5 stars$1.00+2.7%$6.00+500.0%-18.8%$29.30M$3.49M-5.007Positive NewsSCYXSCYNEXIS0.9025 of 5 stars$0.71-1.9%N/A-63.5%$28.29M$3.75M-1.2760Positive News Related Companies and Tools Related Companies Kezar Life Sciences Alternatives Clene Alternatives OnKure Therapeutics Alternatives Rein Therapeutics Alternatives FibroGen Alternatives Biodexa Pharmaceuticals Alternatives Estrella Immunopharma Alternatives MIRA Pharmaceuticals Alternatives Dyadic International Alternatives SCYNEXIS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADXN) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Addex Therapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Addex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADXN Stock Alerts